- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 31.03. | PMLiVE's Top Pharma list - results and predictions for global drug sales | ||
| 28.03. | Merck granted EC approval for adult-specific pneumococcal vaccine Capvaxive | ||
| 28.03. | Biogen unveils plans for new global headquarters and R&D hub in US | ||
| 28.03. | LEO and Reig Jofre partner to improve access to psoriasis therapy in Europe | ||
| 28.03. | PM Society announces launch of PMi Awards 2025 | ||
| 28.03. | Women in pharma | ||
| 27.03. | GSK's antibiotic Blujepa granted FDA approval to treat urinary tract infections | ||
| 27.03. | J&J shares overall survival results for Rybrevant/Lazcluze combination in lung cancer | ||
| 27.03. | FDA approves Soleno's Vykat XR as first treatment for hyperphagia in Prader-Willi syndrome | ||
| 27.03. | Fox&Cat appoints Kim Walker as partner and managing director | ||
| 27.03. | Innovation's one real law | ||
| 26.03. | Merck gains rights to Hengrui's heart disease candidate in deal worth almost $2bn | ||
| 26.03. | Sanofi's investigational MS treatment tolebrutinib granted FDA priority review | ||
| 26.03. | UKHSA releases list of pathogens posing 'greatest risk' to public health | ||
| 26.03. | Mastering KAM excellence: achieving meaningful growth from top accounts | ||
| 25.03. | Novo Nordisk gains rights to United Laboratories' triple receptor agonist in deal worth $2bn | ||
| 25.03. | Novartis' Fabhalta granted FDA approval to treat ultra-rare kidney disease C3G | ||
| 25.03. | GSK to explore link between Shingrix and dementia risk in new UK research collaboration | ||
| 25.03. | Breaking boundaries in medical affairs: how measurable outcomes redefine success | ||
| 24.03. | Johnson & Johnson to invest more than $55bn in US over next four years | ||
| 24.03. | AstraZeneca announces $2.5bn investment in China to boost R&D capabilities | ||
| 24.03. | Alnylam's Amvuttra granted FDA approval for rare heart disease ATTR-CM | ||
| 24.03. | From zero to hero: is zero-party data your new best friend for omnichannel HCP engagement? | ||
| 21.03. | Roche and Oxford BioTherapeutics enter oncology partnership worth over $1bn | ||
| 21.03. | Johnson & Johnson's Tremfya granted FDA approval to treat Crohn's disease |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
